Advertisement
Advertisement
RNA
Atrium Therapeutics, Inc. Common Stock
14.83
USDSponsored
-0.64
-4.14%
Mar 06, 15:59 UTC -5
Closed
After-Market
14.82
0.00
-0.03%
RNA Earnings Reports
Positive Surprise Ratio
RNA beat 12 of 22 last estimates.
55%
Next Report
Next Week
Date of Next Report
Mar 03, 2026
Estimate for Q4 25 (Revenue/ EPS)
$3.38M
/-$1.27
Implied change from Q3 25 (Revenue/ EPS)
-72.87%
/--
Implied change from Q4 24 (Revenue/ EPS)
+13.85%
/+58.75%
Atrium Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 10, 2025, RNA reported earnings of -1.27 USD per share (EPS) for Q3 25, missing the estimate of -1.11 USD, resulting in a -14.20% surprise. Revenue reached 12.47 million, compared to an expected 2.11 million, with a 490.09% difference. The market reacted with a +1.23% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analysts forecast an EPS of -1.27 USD, with revenue projected to reach 3.38 million USD, implying an increase of 0.00% EPS, and decrease of -72.87% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Liquidia Corporation Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.18
Actual
$0.15
Surprise
-18.48%
Kura Oncology, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.62
Actual
-$0.92
Surprise
-47.84%
CorMedix Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.83
Actual
$0.61
Surprise
-26.73%
REGENXBIO Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.97
Actual
-$1.30
Surprise
-33.31%
Lexicon Pharmaceuticals, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.04
Surprise
+43.18%
Contineum Therapeutics, Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.41
Actual
-$0.49
Surprise
-18.41%
Verastem, Inc.
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.53
Actual
-$0.50
Surprise
+7.32%
Lineage Cell Therapeutics, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.05
Actual
$0.00
Surprise
+100.00%
Atea Pharmaceuticals, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.54
Actual
-$0.56
Surprise
-5.44%
Aligos Therapeutics, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$1.88
Actual
-$1.91
Surprise
-1.11%
FAQ
What were Atrium Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Atrium Therapeutics, Inc. Common Stock reported EPS of -$1.27, missing estimates by -14.2%, and revenue of $12.47M, 490.09% above expectations.
How did the market react to Atrium Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 1.23%, changed from $69.84 before the earnings release to $70.70 the day after.
When is Atrium Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 03, 2026.
What are the forecasts for Atrium Therapeutics, Inc. Common Stock's next earnings report?
Based on 14
analysts, Atrium Therapeutics, Inc. Common Stock is expected to report EPS of -$1.27 and revenue of $3.38M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement